Lenvakast 4 lenvatinib

Levagen 4mg Breast Cancer Levagen is recommended as a standalone treatment for adult patients with confirmed or suspected deleterious germline BRCA mutations gBRCAm and human epidermal growth factor receptor 2 HER2 negative metastatic breast cancer These individuals should have undergone prior chemotherapy in the neoadjuvant, adjuvant, or metastatic setting For those with hormone receptor HR positive breast cancer, progression on or unsuitability for endocrine therapy is a prerequisite It is essential to confirm the germline BRCA mutation before initiating Olanib treatment Ovarian Cancer Levagen is suggested as a standalone treatment for the maintenance of adult patients with platinum sensitive relapsed PSR high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer This applies to individuals who have responded complete or partial response to platinum based chemotherapy.